Cognyte stock initiated with Buy rating at Roth/MKM on intelligence analytics leadership

Roth/MKM initiated coverage on Cognyte Software (CGNT) with a Buy rating and a $14 price target, citing its leadership in intelligence analytics, accelerating growth, and strong recurring revenue, noting the stock trades at a discount to peers on an EV/FCF basis. This follows Cognyte's mixed Q2 FY25 results, which saw an EPS miss but a revenue beat, and the securing of a significant one-year, $20M+ support agreement with a key national security client.

Analysis

Roth/MKM has initiated coverage on Cognyte Software Ltd. (CGNT) with a 'Buy' rating and a $14.00 price target, signaling significant potential upside from its current $8.25 trading level. The firm's bullish thesis is anchored in Cognyte's market leadership in Intelligence Analytics, its accelerating growth, and improving margins. Roth/MKM highlights a valuation disconnect, noting the stock trades at approximately 12x FY27E EV/FCF, a discount to growth-adjusted peers, while their target is based on a 20x multiple. This positive outlook is supported by strong business fundamentals, including a high degree of revenue visibility with nearly half of its revenues being recurring. However, this analyst optimism is set against a mixed Q2 FY25 financial report, where Cognyte missed EPS estimates by 33.33% ($0.02 vs. $0.03 anticipated) but slightly beat revenue forecasts ($97.5M vs. $95.8M). The EPS miss suggests potential challenges in translating top-line growth to bottom-line profitability. Offsetting this concern is strong operational momentum, evidenced by a newly secured one-year support agreement valued at over $20 million with a long-standing national security client, reinforcing the company's entrenched position in the government sector.

Key Decisions for Investors

• Consider the bullish thesis from Roth/MKM, which identifies a significant valuation gap based on a discounted EV/FCF multiple relative to peers, suggesting a potential re-rating opportunity towards the $14 price target.
• Monitor future earnings reports closely for evidence of margin improvement and profitability conversion, as the recent Q2 EPS miss presents a near-term execution risk despite the revenue beat and strong contract momentum.
• Evaluate the stability provided by the high percentage of recurring revenue and look for further announcements of major contracts, like the recent $20M+ deal, as confirmation of the company's sticky relationships with key government clients.